

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17136-003001	Application No. 10/800,361
Information Disclosure Statement by Applicant <small>(Use several sheets if necessary)</small> <small>(37 CFR §1.98(b))</small>		Applicant Gage et al.			
		Filing Date March 11, 2004		Group Art Unit 1648	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
LL	AA	4,681,852	07/21/1987	Tribe			
LL	AB	5,846,757	12/8/1998	Harpold et al.			
	AC						
	AD						
	AE						
	AF						
	AG						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No
LL	AH	34602/89	16 Nov 89	Australia			
	AI						
	AJ						
	AK						
	AL						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
LL	AM	Derwent Abstract Accession No. 92-175825/22, Class B04 D16, DD 297186, A (University Berlin Humboldt), 2 January 1992
LL	AN	Piller et al., "Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers, PNAC"; Vol. 93, pp. 111-115
LL	AO	Yamato et al., "Site specific alteration of arginine 376 the unique positively charged..."; J. Biol. Chem.; Vol. 269, No. 8, pp. 5720-5724
LL	AP	Schubert et al., American Society for Microbiology, 1995, page 63

Examiner Signature 	Date Considered 12/16/05
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	